approved the reviewed financial statements, including the consolidated financial statements of the Company and its subsidiaries for the third quarter and nine month period ended 30th September 2020. The
35.58% 4.57 25.02% 2.76 60.39% Profit for equity holders of the Company 7.35 35.71% 4.59 25.14% 2.76 60.18% Profit for non-controlling interests of the subsidiaries (0.03) (0.13%) (0.02) (0.12%) 0.00
provides services. Page 2 of 7 Table summarized the operating results of the Group (unit : Bt million) This situation significantly affects the Company and its subsidiaries’ business activities in terms of
Limited and its subsidiaries (“Company”) would like to notify the operating result stated in consolidated financial statements for the first Quarter period ended March 31, 2020 compared with the same period
subsidiary not more than 10 percent of the total voting shares in the subsidiary and is not a controlling person on the subsidiary; and this transaction is a transaction between subsidiaries of the same listed
36.06% 10.27 27.89% 3.47 33.76% Profit for equity holders of the Company 13.76 36.13% 10.29 27.95% 3.47 33.72% Profit for non-controlling interests of the subsidiaries (0.03) (0.08%) (0.02) (0.07%) 0.00
Company and its subsidiaries company as of June 30, 2020 , and the said value exceeds 1 million THB but not more than 20 million THB , that is, it is a medium-sized item according to the announcement of the
booked in the subsidiaries’ operational assets. As a result, the Company recognized the financial costs of each project in the income statement. In the third quarter of 2019, the Company was in the process
November 11, 2020 Subject: Management’s Discussion and Analysis for the third quarter of 2020 To: The President The Stock Exchange of Thailand (SET) DOD Biotech Public Company Limited and its subsidiaries
: The President The Stock Exchange of Thailand Takuni Group Public Company Limited (“The Company”) and its subsidiaries (“The Group”) would like to clarify the change in operating result for the period